Skin Affecting Patents (Class 514/18.6)
-
Publication number: 20120121724Abstract: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin, as well as other therapeutic agents either with or without nitroglycerin, through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.Type: ApplicationFiled: January 20, 2012Publication date: May 17, 2012Inventor: Todd Maibach
-
Publication number: 20120121572Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.Type: ApplicationFiled: May 14, 2010Publication date: May 17, 2012Applicant: FIDIA FARMACEUTICI S.P.A.Inventors: Matteo D'Este, Giovanni Gennari
-
Publication number: 20120121591Abstract: Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.Type: ApplicationFiled: March 19, 2010Publication date: May 17, 2012Applicant: Amgen Inc.Inventors: John K. Sullivan, Leslie P. Miranda, Colin V. Gegg, Shaw-Fen Sylvia Hu, Edward J. Belouski, Justin K. Murray, Hung Nguyen, Kenneth W. Walker, Taruna Arora, Frederick W. Jacobsen, Yue-Sheng Li, Thomas C. Boone
-
Publication number: 20120121725Abstract: The present invention relates to a cosmetic, nutraceutical or dermatological composition for treating or preventing acne, comprising a peptide and oside extract of Schizandra fruit and a suitable excipient. Preferably, the extract is obtained from Schizandra sphenanthera. The composition may also comprise at least one anti-acne agent selected from a sebum-regulating agent, an antibacterial and/or antifungal agent, a keratolytic agent and/or a keratoregulating agent, an astringent, an anti-inflammatory and/or anti-irritant, an antioxidant and/or a free-radical scavenger, a cicatrizing agent, an anti-ageing agent and a moisturizing agent. The invention also relates to a method for cosmetic treatment of acne, characterized in that a cosmetic composition according to the invention is applied to the affected areas of the skin, or in that the affected individual takes a nutraceutical composition according to the invention orally.Type: ApplicationFiled: July 27, 2010Publication date: May 17, 2012Inventors: Sebastien Garnier, Dalale Naaimi, Caroline Baudouin
-
Publication number: 20120122763Abstract: The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological conditions in mammals mediated by GPCR or of physiological and/or pathological conditions which can be treated by modulation of these receptors.Type: ApplicationFiled: January 25, 2012Publication date: May 17, 2012Applicant: AETERNA ZENTARIS GmbHInventors: Tilmann SCHUSTER, Klaus Paulini, Peter Schmidt, Silke Baasner, Emmanuel Polymeropoulos, Eckhard Guenther, Michael Teifel
-
Publication number: 20120115773Abstract: The method of the invention relates to a modified OmCI polypeptide or a polynucleotide encoding a modified OmCI polypeptide which lacks LK/E binding activity and the use of such polypeptides and polynucleotides for the treatment of a disease or condition mediated by complement.Type: ApplicationFiled: February 4, 2010Publication date: May 10, 2012Inventors: Miles A. NUNN, Susan M. Lea, Pietro Roversi
-
Publication number: 20120114617Abstract: Synthetic peptide including the sequence KKLRIKSKEK (SEQ ID 1) or a sequence of identical size, in which the K residue (in position 1) and the R residue (in position 4) are conserved, the sequence being able to bind to the syndecan-1 receptor.Type: ApplicationFiled: March 15, 2010Publication date: May 10, 2012Applicants: Symatese, Universite Claude Bernard Lyon I, Centre National De La Recherche ScientifiqueInventor: Patricia Rousselle
-
Publication number: 20120114690Abstract: The present disclosure provides an external use composition for skin comprising a tarajo holly leaf extract and a Japanese knotweed leaf extract, a brown algae extract and an egg shell membrane derived peptide (ESM-P) having a molecular mass of 3 kDa or higher. The composition according to the present invention can be used to treat a disease or condition of skin relating to a filaggrin metabolism anomaly, such as atopic dermatitis. The composition according to the present invention can be used specifically for the therapy of atopic dermatitis.Type: ApplicationFiled: November 4, 2011Publication date: May 10, 2012Inventors: Hifumi OHISHI, Keizou Ohishi, Tetsuya Oishi, Hisanori Tani
-
Publication number: 20120114703Abstract: Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.Type: ApplicationFiled: August 18, 2011Publication date: May 10, 2012Applicant: ALLERGAN, INC.Inventor: Patricia S. Walker
-
Publication number: 20120107412Abstract: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In preferred embodiments, the methods and agents comprise active extracts produced from fish eggs. The invention further provides processes for making active fish egg extracts.Type: ApplicationFiled: May 5, 2011Publication date: May 3, 2012Applicant: Regenics ASInventors: Runhild Gammelsaeter, Jan Remmereit
-
Publication number: 20120107410Abstract: The present invention relates to a product obtained from gastropod spawn, to be used to prepare dermatological, cosmetic or cosmeceutical compositions designed for skin care; said product has the capacity to activate and mobilise skin stem cells, as well as prevent the loss thereof that takes place as a consequence of chronological and premature ageing. The present invention also relates to the process followed in order to obtain said product.Type: ApplicationFiled: January 28, 2010Publication date: May 3, 2012Applicant: Industrial Farmaceutica Cantabria, S.A.Inventors: Marta Dominguez Valdes-Hevia, Aurora Brieva Delgado, Salvador Gonzalez Rodriguez, Eduardo Reyes Martin, Jose Carballeira Morado, Ernesto Quintana Gonzalez, Juan Pablo Pivel Ranieri, Antonio Guerrero Gomez-Pamo, Angeles Juarranz De La Fuente, Jesus Espada Regalado, Francisco Sanz Rodriguez
-
Publication number: 20120100106Abstract: Methods and compositions for promoting wound healing in a patient by administering a collagen-binding synthetic peptidoglycan to the patient are described. Additionally, methods and compositions are described for decreasing scar formation in a patient by administering a collagen-binding synthetic peptidoglycan to the patient.Type: ApplicationFiled: May 4, 2010Publication date: April 26, 2012Applicant: PURDUE RESEARCH FOUNDATIONInventors: Alyssa Panitch, John E. Paderi
-
Patent number: 8163694Abstract: The present invention concerns improved osteoinductive materials comprising matrix materials and morphogenetic proteins, wherein depending on the subject matter the proteins may be dimeric or monomeric proteins. The osteoinductive materials according to the present invention have improved properties. The invention further concerns methods for producing the respective improved osteoinductive materials.Type: GrantFiled: December 17, 2008Date of Patent: April 24, 2012Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Jens Pohl, Rolf Bechtold, Michael Kruse
-
Publication number: 20120094921Abstract: The invention concerns a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, a peptide hydrolyzate which is enriched in soothing bioactive peptide. The invention also concerns the use, in a cosmetic composition, of the active principle in accordance with the invention to activate HMG-CoA reductase in skin cells and to prevent or combat skin irritations.Type: ApplicationFiled: April 15, 2010Publication date: April 19, 2012Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20120094920Abstract: The invention relates to a peptidic hydrolyzate enriched in bioactive peptide, capable of reinforcing the skin barrier function and stimulating epidermal differentiation. The invention is also relative to a cosmetic and/or pharmaceutical composition comprising, in a physiologically acceptable medium, said hydrolyzate as active principle. The invention further relates to the use, in a cosmetic composition, of the active principle according to the invention to activate the HMG-CoA reductase in the cutaneous cells, and to prevent and combat the cutaneous signs of aging and photo-aging.Type: ApplicationFiled: April 15, 2010Publication date: April 19, 2012Applicant: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20120088733Abstract: Disclosed are novel antimicrobial peptides which can promote the regeneration of skin cells, thus healing wounds. Pharmaceutical compositions comprising the peptides as active ingredients are also provided for wound healing and skin rejuvenation. The antimicrobial peptides exhibit inhibitory activity against antibiotic-resistant strains, and their antimicrobial activity is maintained without loss of structural stability even under a high salt condition. Also, being proven to promote the migration and regeneration of skin cells in mice as well as in vitro, the antimicrobial peptides may be widely used as an agent for regenerating skin cells. Further, they can find applications in various fields including the medical industry and the cosmetic industry. Hence, the novel antimicrobial peptides are anticipated to have considerable repercussions in the market for antibiotics, wound healing agents and cosmetics.Type: ApplicationFiled: April 27, 2011Publication date: April 12, 2012Applicant: Korea Advanced Institute of Science and TechnologyInventors: Sun-Chang Kim, Da-Jung Kim, Su-A Jang, Bong Hyun Sung, Ki-Jung Lim, Ju-Ri Shin, Young Woong Lee
-
Publication number: 20120083445Abstract: Disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of I?I, wherein the transfer of the heavy chain of I?I is catalyzed by TSG-6. Further disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of I?I, wherein the transfer of the heavy chain of I?I is catalyzed by the TSG-6 like protein.Type: ApplicationFiled: April 26, 2010Publication date: April 5, 2012Applicant: TissueTech, Inc.Inventors: Scheffer Tseng, Hua He
-
Patent number: 8148327Abstract: Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.Type: GrantFiled: June 6, 2008Date of Patent: April 3, 2012Assignees: Human Matrix Sciences, LLC, The Hospital for Sick ChildrenInventors: Thomas Mitts, Aleksander Hinek
-
Publication number: 20120077750Abstract: This invention relates to the inhibition of a newly discovered growth-stimulating protein in an individual. Further, the invention relates to a method for preventing or treating a cancer, or preventing or treating cancer growth, invasion or metastasis, or preventing or treating other hyperproliferative diseases in an individual, by down regulating the expression of said growth-stimulating protein or by inactivating said protein. Still further, the invention concerns a method for diagnosing cancer or other hyperproliferative diseases in an individual based on said growth-stimulating protein.Type: ApplicationFiled: September 27, 2011Publication date: March 29, 2012Inventors: Jukka WESTERMARCK, Pietri PUUSTINEN, Melissa JUNTTILA
-
Publication number: 20120077733Abstract: The invention relates to polypeptides of amino acid sequence SEQ ID NO: 1 according to formula (1), the use thereof for producing a medicament, and medicaments for the treatment of diseases related to monocyte recruitment.Type: ApplicationFiled: December 8, 2011Publication date: March 29, 2012Applicant: RWTH AACEHNInventors: Christian Weber, Philipp Von Hundelshausen, Rory Koenen
-
Publication number: 20120077732Abstract: The present invention relates to cyclic peptides, comprising alternating D- and L- amino acids and wherein the peptide possesses immunomodulatory activity. The present invention also relates to pharmaceutical compositions comprising the cyclic peptides and to methods for the treatment of disease.Type: ApplicationFiled: November 24, 2009Publication date: March 29, 2012Applicant: SYDNEY WEST AREA HEALTH SERVICEInventors: Nicholas Manolios, Veronika Judit Bender, Marina Ali
-
Publication number: 20120079614Abstract: The invention concerns compounds, compositions and methods for the treatment of skin cells. Described herein are CD109 polypeptides and uses thereof for the in vivo treatment of various skin disorders, including skin fibrosis, skin scarring, wound healing and psoriasis.Type: ApplicationFiled: February 19, 2010Publication date: March 29, 2012Applicant: The Royal Institution for the Advancement of Learning/McGill UniversityInventors: Anie Philip, Joshua Vorstenbosch, Carter Li, Kenneth Finnson, Hahn Soe-Lin, Xiao-Yong Man, Albane Bizet, Hasan Al-Ajmi
-
Publication number: 20120077731Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, 1L-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: ApplicationFiled: April 12, 2010Publication date: March 29, 2012Applicant: Ablynx N.V.Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
-
Publication number: 20120071414Abstract: The present invention relates to a method for extracting organic molecules and/or organic minerals from a limestone material, including placing said limestone material in contact with a solution including at least one organic solvent, water and at least one acid, as well as to the organic molecules and/or organic minerals produced by the method. The products produced by the method can be used, for example, in therapeutic and non-therapeutic fields, in particular the agri-food, cosmetic and medical fields.Type: ApplicationFiled: April 9, 2010Publication date: March 22, 2012Applicants: Centre National De La Recherche Scientifique-CNRS-, Universite D'Orleans, Museum National D'Histoire NaturelleInventors: Xavier Bourrat, Evelyne Lopez, Marthe Rousseau
-
Publication number: 20120070392Abstract: The present invention relates to a composition for inhibiting erythema caused by ultraviolet radiation, wherein said composition contains a specific dipeptide, selected from 400 dipeptides, as an active ingredient. The composition of the present invention inhibit the production of prostaglandin E2(PEG2), thereby inhibiting erythema caused by ultraviolet radiation.Type: ApplicationFiled: March 30, 2010Publication date: March 22, 2012Inventors: Hyun-Kyung Lee, Hye-Ryung Choi, Youn-A Kang
-
Publication number: 20120071394Abstract: The present invention provides a polypeptide having a biological activity of the Chemotaxis Inhibitory Protein of Staphylococcus aureus (‘CHIPS’), the polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2, or a fragment or variant thereof having a biological activity of CHIPS, wherein the fragment or variant retains amino acid substitutions K40E, D42V, N77H, K100R, K105R, N111 K and/or G112A relative to the wildtype CHIPS protein of SEQ ID NO:1. In one embodiment, polypeptide consists of the amino acid sequence of SEQ ID NO: 2. Related aspects of the invention provide pharmaceutical compositions comprising a polypeptide of the invention, together with methods or making and using the same.Type: ApplicationFiled: November 30, 2009Publication date: March 22, 2012Inventors: Christina Furebring, Anna Rosén, Karin Haraldsson, Erika Gustafsson, Björn Ulrik Walse
-
Publication number: 20120065131Abstract: The invention relates to the transdermal application of oligopeptides for reducing synaptic transmission in tissues of an animal. In one aspect, this invention relates to compositions comprising an oligopeptide and optionally a carrier comprising a positively charged “backbone” having positively charged branching or “efficiency” groups, as described herein. Most preferably the positively charged carrier is a long-chain positively charged polypeptide or a positively charged nonpeptidyl polymer, for example, a polyalkyleneimine. The invention further relates methods for producing a biologic effect of reducing synaptic transmission in a tissue by topically applying an effective amount of such a composition, preferably to the skin, of a subject or patient in need of such treatment.Type: ApplicationFiled: August 29, 2011Publication date: March 15, 2012Applicant: Revance Therapeutics, Inc.Inventors: Michael D. Dake, Jacob M. Waugh
-
Publication number: 20120065144Abstract: It comprises an inhibitor peptide of TGF-?1 for use in preventive or therapeutic treatment of skin tumors at early stages, in which the peptide is disitertide or a derivate thereof, and a pharmaceutical composition that comprises a therapeutically effective amount of the peptide.Type: ApplicationFiled: March 4, 2010Publication date: March 15, 2012Applicant: ISDIN, S.A.Inventors: Raul Insa Boronat, Miguel Quintanilla Avila, Javier Dotor De Las Herrerias
-
Patent number: 8133487Abstract: The present invention provides methods of treating psoriasis in a subject (i.e., psoriasis associated with a joint disease), by administering to the subject an effective dose of a composition comprising a soluble IL-22R/IL-20RB heterodimeric polypeptide, wherein the heterodimeric polypeptide comprises an IL-22R extracellular domain covalently linked to an IL-20RB extracellular domain.Type: GrantFiled: January 27, 2010Date of Patent: March 13, 2012Assignee: ZymoGenetics, Inc.Inventors: Yasmin A. Chandrasekher, Julia E. Novak, Donald C. Foster, Wenfeng Xu, Stephen R. Jaspers
-
Publication number: 20120058934Abstract: The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering an effective amount of a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification. The invention further provides a kit. The kit comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification.Type: ApplicationFiled: September 7, 2011Publication date: March 8, 2012Applicant: DMI ACQUISITION CORP.Inventor: David Bar-Or
-
Publication number: 20120058086Abstract: Compositions, kits and methods for promoting diabetic wound healing are based on the discovery that SDF-1? specifically upregulates expression of E-selectin in mature endothelial cells (EC), leading to an increase in EC-endothelial progenitor cell (EPC) adhesion and EPC homing. Methods for promoting healing of a wound in a diabetic subject include providing a therapeutically effective amount of a composition including E-selectin protein or a nucleic acid encoding E-selectin protein, and optionally, an agent that specifically upregulates E-selectin expression (e.g., SDF-1?). The methods can also include administering hyperbaric oxygen treatment to the subject. Administering the composition to the subject results in migration of bone marrow-derived progenitor cells to the wound, accelerated wound healing, and upregulation of E-selectin expression in the subject.Type: ApplicationFiled: April 9, 2010Publication date: March 8, 2012Inventors: Omaida C. Velazquez, Zhao-Jun Liu
-
Publication number: 20120058952Abstract: The present invention relates to a peptide of general formula (I): R1-(AA)n-X1-Gly-Glu-Leu-Ser-X2-X3-(AA)p-R2, derived from human HMG-CoA reductase. The present invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically suitable medium. The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to prevent and/or combat the external stresses and signs of cutaneous aging.Type: ApplicationFiled: December 23, 2009Publication date: March 8, 2012Applicant: ISP INVESTMENTS INC.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20120046217Abstract: The present invention relates to: TNF-? antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-? antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof; a vector containing the polynucleotide; a transformant containing the vector; and a method for screening a therapeutic agent for TNF-? overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNER1.Type: ApplicationFiled: June 30, 2009Publication date: February 23, 2012Applicant: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATIONInventors: Je-Ho Lee, Jae-Ryoung Hwang, Jae-Ho Huh
-
Publication number: 20120039902Abstract: The present invention relates generally to binding agents useful in the selective depletion of T cells in vivo. More specifically, the invention relates to ICOS-binding agents which once bound to ICOS expressed on the surface of cells, in particular ICOS-bearing activated T cells, result in the in vivo depletion of cells to which they are bound. Methods of treating T cell related diseases using said ICOS-binding agents, and pharmaceutical compositions comprising said ICOS-binding agents, a method of identifying an ICOS-binding agent, and monoclonal anti-ICOS antibodies capable of eliminating cells in vivo which express ICOS on their surface are also provided.Type: ApplicationFiled: April 22, 2005Publication date: February 16, 2012Inventor: Richard Kroczek
-
Publication number: 20120027705Abstract: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In some embodiments, the invention relates to compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products.Type: ApplicationFiled: October 6, 2011Publication date: February 2, 2012Applicant: REGENICS ASInventors: Runhild Gammelsaeter, Jan Remmereit
-
Patent number: 8106017Abstract: The present invention relates to a peptide comprising a specific amino acid sequence possessing human thymosin ?-4 (T?4) activities and its uses. The peptide of this invention has identical or similar functions or actions to human T?4 and its biological activity is almost identical to natural-occurring T?4. In addition, the peptide of this invention exhibits much higher stability and skin permeation than natural-occurring T?4. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on improvement in thymosin ?-4-effective disorders or conditions. In addition, the peptide of this invention can be advantageously applied to drugs, cosmetics, toothpaste and compositions for mouth cleaning and caring, most preferably, cosmetics. Specifically, the peptide of this invention is advantageously applied to cosmetics for promoting hair growth.Type: GrantFiled: October 24, 2006Date of Patent: January 31, 2012Assignee: Caregen Co., Ltd.Inventors: Yong Ji Chung, Young Deug Kim, Chung Ryul Kim
-
Publication number: 20120021987Abstract: The invention provides for a mucin3 polypeptide, a polypeptide including a mucin3 EGFlike domain, and nucleic acids encoding such polypeptides. The invention also provides for methods of treating an individual that has or is at risk of developing a disease or condition of the alimentary canal using such polypeptides or nucleic acids.Type: ApplicationFiled: February 7, 2011Publication date: January 26, 2012Applicant: MuciMed, Inc.Inventors: Samuel B. Ho, Laurie L. Shekels
-
Publication number: 20120021029Abstract: Peptides of general formula (I): R1-AA1-AA2-AA3-R2??(I) its stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of conditions, disorders and/or diseases of the skin and/or hair.Type: ApplicationFiled: April 16, 2010Publication date: January 26, 2012Applicant: LIPOTEC, S.A.Inventors: Nuria Garcia Sanz, Wim Van Den Nest, Cristina Carreno Serraima, Antonio Ferrer Montiel, Juan Cebrian Puche, Nuria Alminana Domenech
-
Publication number: 20120021078Abstract: A complete nutritional composition comprising polyphenols is provided for reducing the symptoms of allergies originating from food allergens in young children or infants. Preferably the composition modulates the secondary prevention of allergies while not affecting significantly the primary prevention. The composition comprises an apple extract.Type: ApplicationFiled: April 23, 2010Publication date: January 26, 2012Applicant: NESTEC S.A.Inventors: Sebastien Holvoet, Annick Mercenier, Adrian Zuercher
-
Publication number: 20120014886Abstract: The present invention relates to a soothing cosmetic or pharmaceutical composition comprising at least one peptide that activates human HMG-CoA reductase of general formula (I): R1-(AA)n-X1-Gly-Lys-X2-(AA)p-R2 and sequence SEQ ID No. 1 to SEQ ID No. 10, in a physiologically suitable medium. The present invention further relates to the utilization of this novel peptide as a soothing active principle in a cosmetic composition. The invention further applies to a cosmetic treatment method intended to combat skin irritations.Type: ApplicationFiled: December 23, 2009Publication date: January 19, 2012Applicant: ISP INVESTMENTS INC.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20120014876Abstract: The invention is in the field of molecular medicine. It provides antagonistic compounds for frizzled 1 and/or frizzled 2 receptors, which may be useful in molecular imaging of the wound healing process after myocardial infarction and in therapeutic intervention into wound healing after remodeling of the heart, thereby ameliorating the consequences of myocardial infarction. The invention provides a method for antagonizing frizzled-1 or frizzled-2 receptors, wherein the receptor is contacted with a composition comprising a linear fragment of Wnt3(a) or Wnt5a or a functional analogue thereof, which comprises at least one cysteine residue, one threonine residue, one aspartic acid residue and one glycine residue.Type: ApplicationFiled: February 18, 2010Publication date: January 19, 2012Applicants: ACADEMISCH ZIEKENHUIS MAASTRICHT, UNIVERSITEIT MAASTRICHTInventors: Wessel Matthijs Blankesteijn, Hilde Laeremans, Tilman Mathias Hackeng
-
Publication number: 20120010146Abstract: An injectable composition having dermal filling and tissue expanding activity comprises (1) a quantity of elastin sufficient to bring about dermal filling and tissue expansion when injected into a subject in need of dermal filling and tissue expansion, and (2) a pharmaceutically acceptable carrier. The composition can further comprise collagen, in other alternatives, the composition can further comprise hyaluronic acid, and one or more of the elastin, the collagen, and the hyaluronic acid, if present can be cross-linked, either intramolecularly or intermolecularly.Type: ApplicationFiled: November 3, 2009Publication date: January 12, 2012Applicant: HANCOCK JAFFE LABORATORIES, INC.Inventors: Bo Han, Marcel E. Nimni
-
Publication number: 20120010150Abstract: The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.Type: ApplicationFiled: September 8, 2011Publication date: January 12, 2012Inventors: Jose Engelmayer, Atul Varadhachary
-
Publication number: 20120010149Abstract: The invention relates to a peptide combination characterized by peptides each having the same sequence length (SEQL), that can be produced from a mixture (A) comprising a number x of amino acids having a protected acid group or a number z of peptides having an acid group protected by means of a protecting group and an activated amino group, wherein the amino acids are present in the mixture (A) in particular adjustable molar ratios, and a mixture (B) comprising a number y of amino acids having an amino group protected by means of a protecting group, wherein the amino acid molar ratios of the mixture (B) are equal to the amino acid molar ratios of the mixture (A), and wherein the number x=y.Type: ApplicationFiled: December 30, 2009Publication date: January 12, 2012Applicant: GKL-Biotec AGInventor: Guenther Klett-Loch
-
Publication number: 20110319330Abstract: The instant invention provides a method of treating an animal suffering a disease characterized by excessive apoptosis by administering a therapeutically effective amount of at least one serine protease inhibitor and thereafter monitoring a decrease in apoptosis. The inhibitor of the invention includes ?1-antitrypsin or an ?1-antitrypsin-like agent, including, but not limited to oxidation-resistant variants of ?1-antitrypsin, and peptoids with antitrypsin activity. The diseases treatable by the invention include cancer, autoimmune disease, sepsis neurodegenerative disease, myocardial infarction, stroke, ischemia-reperfusion injury, toxin induced liver injury and AIDS. The method of the invention is also suitable for the prevention or amelioration of diseases characterized by excessive apoptosis.Type: ApplicationFiled: April 27, 2010Publication date: December 29, 2011Applicant: BIO HOLDING, INC.Inventor: LeLand Shapiro
-
Publication number: 20110319317Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of Sirtuin 1 (SIRT1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SIRT 1.Type: ApplicationFiled: March 3, 2010Publication date: December 29, 2011Applicant: OPKO CuRNA, LLCInventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
-
Publication number: 20110318433Abstract: The present invention relates to a soothing cosmetic or pharmaceutical composition comprising at least one peptide that activates human HMG-CoA reductase of general formula (I): R1-(AA)n-X1-Gly-Glu-Leu-Ser-X2-X3-(AA)p-R2 and a physiologically suitable medium. The present invention further relates to the utilization of this novel peptide as a soothing active principle in a cosmetic composition. The invention further applies to a cosmetic treatment method intended to combat skin irritations.Type: ApplicationFiled: December 23, 2009Publication date: December 29, 2011Applicant: ISP INVESTMENTS INC.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20110311564Abstract: The present invention relates to the use of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof, for a treatment in a variety of conditions, such as the induction of immunotolerance, autoimmune diseases, bacterial infections, and proliferative diseases, such as cancers.Type: ApplicationFiled: June 23, 2009Publication date: December 22, 2011Inventors: Markus Kalesse, Leíla Bülow, Andreas Rentsch, Anna-Katharina Girbig, Ulrike Eggert, Nisar Malek, Ronald Frank, Tobias Brodmann
-
Publication number: 20110311529Abstract: The present invention relates to compositions and methods for treating rheumatic diseases, such as psoriasis arthropathica, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.Type: ApplicationFiled: July 27, 2011Publication date: December 22, 2011Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
-
Publication number: 20110311613Abstract: Described herein, are topical formulations for treating a dermatological disease, disorder, or condition.Type: ApplicationFiled: December 21, 2009Publication date: December 22, 2011Applicant: AMIRA PHARMACEUTICAL, INC.Inventors: John Howard Hutchinson, Jillian F. Evans, Kevin Murray Schaab